ArticleBMJ open2020
What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- A dual domain systematic review and meta-analysis of risk tool accuracy to predict cardiovascular morbidity in prehypertension and diabetic morbidity in prediabetes.Frontiers in endocrinology · 2025Pooled it
- Cost-effectiveness of the ABCStroke pathway in ischaemic stroke care: a UK pilot analysis.European heart journal. Quality of care & clinical outcomes · 2026Article
- Improving case-finding of long-term health problems in disadvantaged communities: A Policy-focused Evidence Brief.Public health in practice (Oxford, England) · 2026Article
- Evaluating a Preventive Heart Health Program for Women at Midlife: Protocol for a Mixed Methods Pilot Study.JMIR research protocols · 2026Article
- Highlights from the Manifesto on the Health Economics of Cardiovascular Disease Prevention.PharmacoEconomics · 2025Review
- Article
- Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine coronary computed tomography angiography.European heart journal. Quality of care & clinical outcomes · 2025Article
- Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- [Cardiovascular prevention in Saxony-Anhalt : Necessity and new perspectives].Innere Medizin (Heidelberg, Germany) · 2024Review
- Twenty years on from the introduction of the high risk strategy for stroke and cardiovascular disease prevention: a systematic scoping review.European journal of neurology · 2024Article
- NHS Health Check attendance is associated with reduced multiorgan disease risk: a matched cohort study in the UK Biobank.BMC medicine · 2024Article
- Relationships between sodium, fats and carbohydrates on blood pressure, cholesterol and HbA1c: an umbrella review of systematic reviews.BMJ nutrition, prevention & health · 2024Article
- Transforming global approaches to chronic disease prevention and management across the lifespan: integrating genomics, behavior change, and digital health solutions.Frontiers in public health · 2023Review
- Diabetes and Cardiovascular Diseases Risk Assessment in Community Pharmacies: An Implementation Study.International journal of environmental research and public health · 2022Article
- What factors influence differential uptake of NHS Health Checks, diabetes and hypertension reviews among women in ethnically diverse South London? Cross-sectional analysis of 63,000 primary care records.EClinicalMedicine · 2022Article
- NHS Health Check programme: a rapid review update.BMJ open · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the cost savings and health benefits of improving detection of individuals at high risk of cardiovascular disease (CVD) in England, to determine to which patient subgroups these benefits arise, and to compare different strategies for subsequent management.
designAn economic analysis using the School for Public Health Research CVD Prevention Model.
settingEngland 2018.
participantsAdults aged 16 and older with one or more high cardiovascular risk conditions, including hypertension, diabetes, non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol.
interventionsDetection of 100% of individuals with CVD high risk conditions compared with current levels of detection in England. Detected individuals are assumed to be managed either according to current levels of care or National Institute of Health and Care Excellence (NICE) guidelines.
main outcome measuresIncremental and cumulative costs, savings, quality adjusted life years (QALYs), CVD cases, and net monetary benefit, from a UK NHS and Personal Social Services perspective.
results£68 billion could be saved, 4.9 million QALYs gained and 3.4 million cases of CVD prevented over 25 years if all individuals in England with the six CVD high risk conditions were diagnosed and subsequently managed at current levels. Additionally, if all detected individuals were managed according to NICE guidelines, total savings would be £61 billion, 8.1 million QALYs would be gained and 5.2 million CVD cases prevented. Most benefits come from detection of high cholesterol in the short term and diabetes in the long term.
conclusionsSubstantial cost savings and health benefits would accrue if all individuals with conditions that increase CVD risk could be diagnosed, with detection of undiagnosed diabetes producing greatest benefits. Ensuring all conditions are managed according to NICE guidelines would further increase health benefits. Projected cost-savings could be invested in developing acceptable and cost-effective solutions for improving detection and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.